Functional Role and Mechanism of microRNA-28b in Atrial Myocyte in a Persistent Atrial Fibrillation Rat Model

Yongbin Wang, Weiqiang Kang, Xu Wang, Meina Chen, Qiaoji Qin, Minglei Guo, Zhiming Ge

Background: Persistent atrial fibrillation has been indicated to be related with microRNA-28b. However, the exact role of microRNA-28b in persistent atrial fibrillation needs to be further elucidated. Therefore, this study aimed to establish a rat model of persistent atrial fibrillation to investigate the level of microRNA-28b in atrial myocytes and to explore the molecular mechanism involved.

Material/Methods: A persistent atrial fibrillation model was established in rats by using chronic rapid atrial pacing induction. The size of the heart was measured by ultrasonic method. The expression of microRNA-28b in left atrial myocytes was quantified by RT-PCR. Cardiomyocytes were isolated and cultured to detect cell proliferation and apoptosis by MTT and flow cytometry, respectively. The specific inhibitor of ERK signaling pathway, PD98059, was used to further illustrate the role of ERK signaling pathway in the modulation of cardiomyocytes in persistent atrial fibrillation.

Results: MicroRNA-28b was up-regulated in the experimental rat model with persistent atrial fibrillation. The proliferation of cardiomyocytes was significantly inhibited with potentiated apoptosis. Blockage of the ERK pathway suppressed the microRNA-28b expression and inhibited cell apoptosis.

Conclusions: microRNA-28b-induced growth inhibition and cell apoptosis of atrial myocytes was observed in the rat model with persistent atrial fibrillation, via activation of the ERK signaling pathway.

MeSH Keywords: Atrial Natriuretic Factor • Cellulose 1,4-beta-Cellobiosidase • Central Nervous System Vascular Malformations • Mitogen-Activated Protein Kinase 3

Full-text PDF: http://www.medscimonit.com/abstract/index/idArt/896780
Background

With the transition of life styles, the incidence of cardiovascular diseases, including persistent atrial fibrillation, is continuously increasing [1]. Persistent atrial fibrillation severely affects quality of life [2]. It is defined as continuous atrial fibrillation that lasts more than 7 days [2,3]. The classical treatment approaches, including medication and surgery, are important in the treatment of persistent atrial fibrillation [4], but also may cause adverse effects, including hemorrhage [5]. Therefore, it is necessary to develop novel therapies that have higher efficacy [6–8].

As a small-molecule RNA, microRNA has a length of between 17 and 23 bp [9,10]. Although not coding proteins, microRNA has pluripotent biological functions, including modulation of cell growth and survival [11], as well as regulating cell proliferation, cell cycle [12], autophagy, and the signaling pathway [13]. microRNAs can improve the therapy of heart failure patients [14] and play an important role in cardiac resynchronization therapy [15]. Furthermore, the microRNA expression has been demonstrated to be altered after atrial fibrillation catheter ablation and could be used as atrial fibrillation fibrotic and electrical alterations biomarkers [16]. A recent study has suggested a correlation between microRNA-28b and persistent atrial fibrillation [17], although its exact function in the structural reconstruction of cardiomyocytes needs further investigation [8]. microRNA-28b has been implicated in modulating cell growth and survival [19]; therefore, this study investigated the potential role of microRNA-28b in cardiomyocytes of rats with persistent atrial fibrillation.

The ERK signaling pathway is mediated by certain serine/threonine kinases [20]; it is widely distributed [21] and mediates cell growth and survival [22], cell proliferation and cell cycle [23], autophagy and signaling pathway [24]. Recent studies showed activation of the ERK pathway in cardiomyocytes during persistent atrial fibrillation in mammals and humans [25,26]. Therefore, dysregulation of cell growth and survival of cardiomyocytes may be a cause of persistent atrial fibrillation [27].

In this study, we generated a rat model of persistent atrial fibrillation, in which the role of microRNA-28b and the ERK signaling pathway in cardiomyocytes were analyzed in conjunction with signaling pathway analysis.

Material and Methods

Animal model

A total of 192 male SD rats (Shandong University, China) were prepared for establishment of a persistent atrial fibrillation model using a chronic rapid atrial pace marker, as previously documented [27]. In brief, a circular pacemaker electrode was fixed on the left superior pulmonary vein. Another recording electrode was fixed on the left atrial wall. One pulse stimulator (1600 per min) was connected to the pacemaker electrode. The stimulus was applied every 2 days, in parallel with electrophysiological recordings. The successful generation of the model was achieved when the duration of persistent atrial fibrillation exceeded 12 h. A sham group was also recruited with electrode implantation but no stimulus.

The establishment of the AF model was defined as a rapid (>800 beats/min) irregular atrial rhythm, and AF inducibility was defined as AF lasting for at least 1 s immediately after the 6-burst cycle protocol. If AF was induced after <6 burst pacing cycles, burst pacing was suspended to avoid interfering with the evolution of AF. AF duration was determined in each rat as the mean duration of all AF episodes.

This study was approved by the Experimental Animal Ethics Committee of Qilu Hospital of Shandong University.

Ultrasonic examination

Using methods previously described [22], we measured all parameters of echocardiography, including ejection fraction, diameter of outflow tract in the right ventricle, and inner diameters of left/right ventricles and atrium.

Isolation and culture of cardiomyocytes

Using previously reported methods [28], we isolated and cultured cardiomyocytes from persistent atrial fibrillation and sham rats. In brief, heart tissues were first digested with 0.1% trypsin and re-suspended in DMEM medium (Gibco, USA) containing 10% fetal bovine serum (FBS). A specific cell-sorting column containing specific antibody against cardiomyocyte markers troponin I and troponin T was used to purify cells for continuous incubation in a humidified chamber at 37°C for 48 h.

MTT assay

ERK signaling pathway inhibitor PD98059 (100 nM) was used to incubate isolated cardiomyocytes for 12 h. After changing the medium at 24 h, MTT assay was performed to detect the growth and survival of cardiomyocytes, as documented previously [29].

Cell apoptosis assay

Cultured cardiomyocytes from the experimental and sham groups were examined for apoptosis using flow cytometry by detecting plasma membrane translocation of phosphatidylserine.
with FITC-Annexin-V dye (Beyotime, China), as previously reported [30]. Caspase-3 activity in cardiomyocytes was measured by test kits (Sigma, USA), as reported previously [31].

**RT-PCR**

Total RNA was extracted from cardiomyocytes of all groups using a previously documented method [32]. RT-PCR was then performed to quantify the level of microRNA-28b using actin as the internal reference. Primers used included: microRNA-28b-forward, 5’-CTCAG AGAGT TTGAT-3’; microRNA-28b-reverse, 5’-AGAGT TTGAT CATGG-3’; actin-forward, 5’-TTAG ACGTT AGAGT-3’; actin-reverse, 5’-TGATA TGAGT CTGAG-3’.

**Western blotting**

Activation of the ERK signaling pathway in experimental and sham rats was tested by Western blot analysis [33]. In brief, all cells were lysed to extract total proteins, which were then separated by SDS-PAGE and transferred onto a PVDF membrane. Antibody against ERK and p-ERK (Beyotime, China) were used to detect protein levels.

**Statistical analysis**

All data were processed in SPSS 13.0 software, and are presented as mean ± standard deviation (SD). One-way analysis of variance (ANOVA) was used to compare means across groups. Statistical significance was defined at p<0.05.

| Group          | Sham (n=96) | Experiment (n=96) | t value | P value |
|----------------|-------------|-------------------|---------|---------|
| LVEF (%)       | 57.20±4.30  | 56.78±4.22        | 0.356   | 0.723   |
| LVIDd (mm)     | 50.75±3.86  | 50.14±4.11        | 0.545   | 0.588   |
| LVIDs (mm)     | 27.55±2.35  | 27.36±2.00        | 0.318   | 0.752   |

LVEF – left ventricle ejection fraction; LVIDd – left ventricle internal diameter at end-diastole; LVIDs – left ventricle internal end systolic diameter.

**Results**

**Echocardiography**

Ultrasonic examination of all rats with induced persistent atrial fibrillation showed no significant structural abnormalities as compared to sham rats. Quantitative parameters, including ejection fraction, inner diameter of right ventricle efflux tract, and inner diameters of left/right ventricle and atrium, all had no significant difference between the 2 groups (Table 1), suggesting no systemic heart disease in model rats.

**MicroRNA-28b expression level**

As shown in Figure 1, microRNA-28b expression level in cardiomyocytes in rats with persistent atrial fibrillation was significantly elevated compared to that in the sham group (P<0.05). MTT assay showed significantly decreased growth of cardiomyocytes in rats with persistent atrial fibrillation vs. those in the sham group (P<0.01).

**Apoptosis of cardiomyocytes**

The percentage of apoptotic cells, as shown by the membrane translocation of phosphatidylserine, was significantly higher in the persistent atrial fibrillation group when compared to the sham group (P<0.05, Figure 3). Moreover, the activity of caspase-3 in model rats was also increased (P<0.01, Figure 4).

---

*Wang Y. et al.: MicroRNA-28b in atrial fibrillation © Med Sci Monit, 2016; 22: 3073-3078*

ANIMAL STUDY

This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
These results suggest the occurrence of apoptosis in cardiomyocytes in the model.

**ERK activation in persistent atrial fibrillation rats**

As shown by Western blot analysis, the phosphorylated form of ERK in cardiomyocytes from model rats was significantly increased (Figure 5), suggesting the activation of the ERK pathway in persistent atrial fibrillation.

**Blocking of ERK activation suppressed cell apoptosis**

We further used a specific blocker of the ERK signaling pathway (PD98059, at 100 nM) to treat cultured cardiomyocytes for 12 h. Results showed significantly decreased apoptosis of cardiomyocytes after treatment with inhibitor (Figure 6), suggesting participation of the ERK signaling pathway in the apoptosis of cardiomyocytes in rats with persistent atrial fibrillation.

**Discussion**

Persistent atrial fibrillation severely affects patient quality of life [2]. A recent study indicated the involvement of microRNA-28b in persistent atrial fibrillation [7], but the role of microRNA-28b in pathogenesis requires further investigation. This study aimed to investigate the correlation between microRNA-28b and disease pathogenesis, in addition to exploring the molecular mechanisms.

We showed elevated expression of microRNA-28b in cardiomyocytes from rats with persistent atrial fibrillation, indicating the potential involvement of microRNA-28b in disease...
pathogenesis. Furthermore, the MTT assay showed inhibited cell growth in cultured cardiomyocytes isolated from model rats, but remarkable apoptosis of cardiomyocytes. Activation of the ERK signaling pathway and consequently elevated cell apoptosis suggested the suppression of cardiomyocyte growth and enhanced apoptosis by microRNA-28b via activating the ERK signaling pathway. Certain limitations existed in this study. First, no clinical samples from persistent atrial fibrillation patients were collected to examine microRNA-28b level, ERK activation, and cardiomyocytes apoptosis. Second, we did not treat model rats or patients to interfere with the microRNA-28b level to observe possible improvement. Third, exogenously transfected microRNA-28b has the inherent problem of lower efficacy, making the determination of the correlation between microRNA-28b and disease difficult. Future studies thus should focus on the RNA interference approach to validate the correlation between microRNA-28b and persistent atrial fibrillation.

Conclusions

Our innovative experimental results show microRNA-28b induces growth inhibition and cell apoptosis of atrial myocytes in a rat model of persistent atrial fibrillation via activating the ERK signaling pathway, suggesting that microRNA-28b might be a novel target in the treatment of persistent atrial fibrillation.

Disclosure of conflict of interest

None.

Figure 5. ERK activation in cardiomyocytes. The p-ERK and ERK expression were examined by Western blot.

Figure 6. ERK pathway and cell apoptosis. (A) PD98059 blocked the phosphorylation of ERK; (B) PD98059 treatment decreased apoptotic cell ratio in vitro. One-way analysis of variance (ANOVA) was used to compare means across groups. The ** P<0.01 represents the comparison of apoptosis cell percentage or p-ERK/ERK value in the model group vs. the sham group.
References:

1. Latchamsetty R, Oral H: Is ablation to termination the best strategy for ablation of persistent atrial fibrillation? Ablation to termination is not the best strategy during ablation. Circ Arrhythm Electrophysiol, 2015; 8(4): 972–80

2. Lee WH, Hsu PC, Chu CY et al: Anemia as an independent predictor of adverse cardiac outcomes in patients with atrial fibrillation. Int J Med Sci, 2015; 12(8): 618–24

3. January CT, Wann LS, Alpert JS et al: 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol, 2014; 64(21): 2246–80

4. Chaikriangkrai K, Valderrabano M, Bala SK et al: Prevalence and implications of subclinical coronary artery disease in patients with atrial fibrillation. Am J Cardiol, 2015; 116(8): 1219–23

5. Bai R, Di Blase L, Mohanty P et al: Proven isolation of the pulmonary vein antrum with or without left atrial roof posterior wall isolation in patients with persistent atrial fibrillation. Heart Rhythm, 2016; 13(1): 132–40

6. Al Halabi S, Qintar M, Hussein A et al: Catheter ablation for atrial fibrillation in heart failure patients: A meta-analysis of randomized controlled trials. JACC Clin Electrophysiol, 2015; 1(3): 200–9

7. Calkins H, Kuck KH, Cappato R et al: 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation. Developed in Partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS), and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Heart Rhythm, 2012; 9(1): 632–96

8. European Heart Rhythm Association (EHRA); European Cardiac Arrhythmia Society (ECAS); American College of Cardiology (ACC); American Heart Association (AHA); Society of Thoracic Surgeons (STS), Calkins H, Brugada J, Packer DL et al: HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: A report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in Partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS), and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Heart Rhythm, 2012; 9(1): 632–96

9. Shim J, Park JH, Lee JY et al: eNOS3 genetic polymorphism is related to post-ablation early recurrence of atrial fibrillation. Yonsei Med J, 2015; 56(5): 1244–50

10. Ad N, Holmes SD, Shuman DJ et al: Amiodarone after surgical ablation for atrial fibrillation: Is it really necessary? A prospective randomized controlled trial. J Thorac Cardiovasc Surg, 2015 [Epub ahead of print]

11. Qi WW, Liu T, Xu G et al: Upstream therapeutic strategies of valsartan and losartan associated with paroxysmal atrial fibrillation among cardiovascular patients enrolled in the intermountain Heart Collaborative Study. Heart Rhythm, 2016; 13(1): 21–27

12. Carquist JF, Knight S, Cawthorn RM et al: Shortened telomere length is associated with paroxysmal atrial fibrillation among cardiovascular patients enrolled in the intermountain Heart Collaborative Study. Heart Rhythm, 2016; 13(1): 21–27

13. Lang Y, Xu J, Schoepf UI et al: Prospectively ECG-triggered sequential dual-source coronary CT angiography in patients with atrial fibrillation: Influence of heart rate on image quality and evaluation of diagnostic accuracy. PLoS One, 2015; 10(7): e0134194

14. Marfella R, Di Filippo C, Potenza N et al: Circulating microRNA changes in heart failure patients treated with cardiac resynchronization therapy: Responders vs. non-responders. Eur J Heart Fail, 2013; 15(11): 1277–88

15. Sarad C, Marella F, Santulli G, Paolisso G: Functional role of miRNA in cardiac resynchronization therapy. Pharmacogenomics, 2014; 15(8): 1159–68

16. Sarad C, Santamaria M, Paolisso G, Marella R: microRNA expression changes after atrial fibrillation catheter ablation. Pharmacogenomics, 2015; 16(16): 1863–77

17. Weil BR, Ozcan C: Cardiomyocyte remodeling in atrial fibrillation and herniating myocardium: Shared pathophysiological traits identify novel treatment strategies? Biomed Res Int, 2015; 2015: 587361

18. Li JY, Wang HJ, Xu B et al: Hyperpolarization activated cation current in cardiac myocytes from pulmonary vein sleeves in the canine with atrial fibrillation. J Geriatr Cardiol, 2012; 9(4): 366–74

19. Schneider C, Setty M, Holmes AB et al: MicroRNA 28 controls cell proliferation and is down-regulated in B-cell lymphomas. Proc Natl Acad Sci USA, 2014; 111(22): 8185–90

20. Xu B, Washington AM, Hinton BT: PTEN signaling through RAF1 proto-oncogene serine/threonine kinase (RAF1)/ERK in the epididymis is essential for male fertility. Proc Natl Acad Sci USA, 2014; 111(52): 18643–48

21. Liu D, Huang Y, Bu D et al: Sulfur dioxide inhibits vascular smooth muscle cell proliferation via suppressing the ERK1/2 protein kinases pathway mediated by Camp/pka signaling. Cell Death Dis, 2014; 5: e12151

22. Karam M, Legay C, Auclair C, Ricort JM et al: Protein kinase D1 stimulates proliferation and enhances tumorigenesis of MCF-7 human breast cancer cells through a MEK/ERK-dependent signaling pathway. Exp Cell Res, 2012; 318(5): 558–69

23. Lee do Y, Choi BK, Lee DG et al: 4-1BB signaling activates the T cell factor 1 effector/beta-catenin pathway with delayed kinetics via ERK signaling and delayed PI3K/AKT activation to promote the proliferation of CD8+ T cells. PLoS One, 2013; 8(7): e69677

24. Lin C, Tsai SC, Tseng MT et al: AKT serine/threonine protein kinase modulates baicalin-triggered autophagy in human bladder cancer T24 cells. Int J Oncol, 2013; 42(3): 993–1000

25. Deshmukh A, Barnard J, Sun H et al: Left atrial transcriptional changes associated with atrial fibrillation susceptibility and persistence. Circ Arrhythm Electrophysiol, 2015; 8(1): 32–41

26. McManus DD, Tanriverdi K, Lin H et al: Plasma microRNAs are associated with atrial fibrillation and change after catheter ablation (the miRhythm study). Heart Rhythm, 2015; 12(1): 3–10

27. Nattel S, Gussach E, Savelyeva I et al: Early management of atrial fibrillation to prevent cardiovascular complications. Eur Heart J, 2014; 35(22): 1448–56

28. Liu Z, Zhou C, Liu Y et al: The expression levels of plasma microRNAs in atrial fibrillation patients. PLoS One, 2012; 7(9): e44906

29. Wang X, Qiu CG, Huang ZW et al: The expression and clinical implication of plasma miR-328 in patients with atrial fibrillation. PLoS One, 2012; 7(9): e44906

30. Xu JG, Gan TY, Tang BP et al: Changes in microRNAs expression are involved in age-related atrial structural remodeling and atrial fibrillation. Chin Med J (Engl), 2013; 126(8): 1458–63

31. Zhao Y, Huang Y, Li W et al: Post-transcriptional regulation of cardiac sodium channel gene SCN5A expression and function by miR-192-5p. Biochim Biophys Acta, 2015; 1852(10 Pt A): 2024–34

32. Girmatsion Z, Biliczki P, Bonauer A et al: Changes in microRNA-1 expression and IK1 up-regulation in human atrial fibrillation. Heart Rhythm, 2009; 6(12): 1802–9

33. Li YD, Hong YF, Yusufuaji Y et al: Upstream therapeutic strategies of valsartan and losartan associated with paroxysmal atrial fibrillation among cardiovascular patients enrolled in the intermountain Heart Collaborative Study. Heart Rhythm, 2016; 13(1): 21–27

34. Li YD, Hong YF, Yusufuaji Y et al: Altered expression of hyperpolarization-activated cyclic nucleotide-gated channels and microRNA-1 and -133 in patients with age-associated atrial fibrillation. Mol Med Rep, 2015; 12(3): 3243–48

Indexed in: [Current Contents/Clinical Medicine] [ISI Expanded] [ISI Alerting System] [Chemical Abstracts/CAS] [Index Copernicus]